News | June 09, 2014

Kalila Medical’s Vado Steerable Sheath for AF Procedures is CE Mark Approved

June 9, 2014 — Kalila Medical’s Vado steerable introducer sheath for vascular and intracardiac access, including atrial fibrillation (AF) procedures, has CE mark approval.

"During an ablation procedure, it is extremely important to have precise control over placement of the ablation catheter," said Karl-Heinz Kuck, M.D., Ph.D., director of cardiology at St. Georg Hospital in Hamburg, Germany. "Currently available sheaths have poor torque response, so accurate positioning can be difficult and time-consuming. A steerable sheath with 1:1 torque response provides better navigation and tip positioning, which allows me to create more precise, effective lesions."

AF is an irregular heartbeat caused by hypertension, heart disease and genetic predisposition and can result in symptoms such as shortness of breath, palpitations, confusion and weakness. If untreated, AF can result in a debilitating stroke. Newer approaches to treatment of AF include an endovascular approach using catheter-based ablation to interrupt pathways in the atria and prevent abnormal impulses from propagating. In 2012, there were 311,000 AF ablation procedures worldwide.

"The Vado steerable sheath addresses the existing shortcomings of currently available sheaths with its unique and patent-protected truVector technology that allows tip deflection without the use of pull wires. It's a simple yet innovative solution to creating a high-performance, uniquely torqueable steerable sheath," said Mike Dineen, president and CEO of Kalila Medical. "The current market for steerable sheaths in AF procedures exceeds $100 million and is growing at a rate of approximately 10 percent annually. We are pleased to move toward commercialization of the Vado sheath in this high growth market."

Limited European market release of the Vado Sheath commenced in the second quarter of 2014.

For more information: www.kalilamedical.com

Related Content

First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Overlay Init